Immunovant, Inc.(IMVT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMVT Immunovant, Inc.

盘前交易 07-24 04:51:11 EDT

39.37

+0.32

+0.82%

盘前39.50

+0.13+0.33%

04:49 EDT

最高39.60	最低38.00	成交量78.41万
今开38.39	昨收39.05	日振幅4.10%
总市值80.83亿	流通市值31.43亿	总股本2.05亿
成交额3,073万	换手率0.98%	流通股本7,983万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":39.37,"timestamp":1784836800000,"preClose":39.05,"halted":0,"volume":784113,"hourTrading":{"tag":"盘前","latestPrice":39.5,"preClose":39.37,"latestTime":"04:49 EDT","volume":1307,"amount":51326.235047999995,"timestamp":1784882959306,"change":0.13,"changeRate":0.003302,"amplitude":0.007874},"delay":0,"changeRate":0.00819462227912933,"floatShares":79831200,"shares":205308917,"eps":-2.77164,"marketStatus":"盘前交易","change":0.32,"latestTime":"07-24 04:51:11 EDT","open":38.39,"high":39.6,"low":38,"amount":30730182.776469,"amplitude":0.040973,"askPrice":39.71,"askSize":20,"bidPrice":38.75,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.77164,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784899800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":39.37,"preHourTrading":{"tag":"盘前","latestPrice":39.5,"preClose":39.37,"latestTime":"04:49 EDT","volume":1307,"amount":51326.235047999995,"timestamp":1784882959306,"change":0.13,"changeRate":0.003302,"amplitude":0.007874},"postHourTrading":{"tag":"盘后","latestPrice":39.37,"preClose":39.37,"latestTime":"19:34 EDT","volume":34135,"amount":1343894.96,"timestamp":1784849649443,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8525899559092086,"impliedVol":0.523,"impliedVolPercentile":0.28},"requestUrl":"/m/hq/s/IMVT/tweets","defaultTab":"tweets","newsList":[{"id":"2636282691","title":"Roivant股价上涨，核心资产IMVT-1402中晚期数据备受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2636282691","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636282691?lang=zh_cn&edition=full","pubTime":"2026-05-20 23:03","pubTimestamp":1779289380,"startTime":"0","endTime":"0","summary":"Roivant Sciences股价在周三交易中上涨，系市场对其子公司Immunovant核心管线IMVT-1402的最新进展及公司即将发布的财报给予积极反应。　　投资者的目光正聚焦于IMVT-1402，这是Immunovant开发的一款用于治疗重症肌无力等自身免疫性疾病的新一代FcRn抑制剂。这一结果促使公司全面转向推进IMVT-1402。　　多家分析机构认为，IMVT-1402的成功有望为Roivant带来超过100亿美元的峰值销售额。有分析指出，与当前股价相比，Roivant可能被低估约20%，其潜在公允价值约为每股35.67美元。目前，Roivant的市值约为220亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-20/doc-inhyqiyc6785051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173936076","title":"异动解读 | Immunovant盘中飙涨31.76%，核心药物IMVT-1402积极试验数据成主要推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1173936076","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173936076?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:35","pubTimestamp":1779287758,"startTime":"0","endTime":"0","summary":"生物制药公司Immunovant, Inc.  今日盘中股价大幅上涨31.76%，表现异常强劲。消息面上，公司今日发布了截至2026年3月31日的第四季度及整个财年的财务业绩，并同步更新了业务进展。然而，推动股价飙升的核心动力来自于其核心在研药物IMVT-1402的积极临床试验数据。数据显示，用于治疗难治性类风湿关节炎的IMVT-1402在临床试验中取得了显著效果。这一积极的临床突破完全盖过了公司财报中公布的季度亏损，极大地提振了市场对公司未来前景的信心，并促使投资者积极买入。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115793286","title":"Immunovant股价因试验数据飙升25%，财报表现被市场忽略","url":"https://stock-news.laohu8.com/highlight/detail?id=1115793286","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115793286?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:57","pubTimestamp":1779285440,"startTime":"0","endTime":"0","summary":"核心要点由于实验性药物IMVT-1402的临床试验数据积极，Immunovant股价飙升25%。Immunovant公布季度亏损1.479亿美元，但其现金状况足以支持IMVT-1402在格雷夫斯病领域的上市。周三，临床突破压倒了Immunovant的财务阵痛，投资者对疲软的季度业绩不屑一顾，转而聚焦其实验性药物IMVT-1402的试验数据。在接受600毫克剂量治疗16周后，该药物显示出了Immunovant所称的“具有临床意义的应答率”。Immunovant预计将在今年下半年提供进一步的最新进展。","market":"us","thumbnail":"https://community-static.tradeup.com/news/2856a80a49d35a8ca80db20e4377411c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/2856a80a49d35a8ca80db20e4377411c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Immunovant股价因试验数据飙升25%，财报表现被市场忽略","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1169533872","title":"异动解读 | Immunovant发布财报及业务进展，股价盘前大涨22.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169533872","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169533872?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:14","pubTimestamp":1779275685,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. (IMVT) 今日盘前股价大幅上涨22.59%，引起了市场的广泛关注。消息面上，公司于盘前发布了截至2026年3月31日的第四季度及整个财年的财务业绩，并同步更新了最新的业务进展。财务数据揭示了公司在报告期内的收入状况、研发投入以及整体资金储备情况，为投资者评估其财务健康度与发展轨迹提供了关键依据。此外，公司详细阐述了核心在研管线的开发进度，包括针对自身免疫性疾病的新型抗体疗法的临床试验数据与监管沟通情况。公司强调了其在推进创新疗法、扩大临床项目以及加强全球运营能力方面的持续努力，并对长期增长前景表达了信心，这增强了市场对其未来潜力的乐观预期。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157544560","title":"Immunovant发布企业动态并公布截至2026年3月31日的第四季度及财年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1157544560","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157544560?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:02","pubTimestamp":1779274935,"startTime":"0","endTime":"0","summary":"Immunovant, Inc.  近日公布了截至2026年3月31日的第四季度及整个财年的财务结果，并同步更新了公司的最新业务进展。财务数据显示了公司在报告期内的收入状况、研发投入以及整体资金储备情况，为投资者评估其发展轨迹与财务健康度提供了关键依据。展望未来，Immunovant概述了下一阶段的战略优先事项，旨在加速产品开发，并为潜在的市场准入奠定基础。公司对其长期增长前景保持信心，并致力于为患者带来变革性治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140742156","title":"财报前瞻｜Immunovant, Inc.本季度营收预计持平，管线试验挫折成变数","url":"https://stock-news.laohu8.com/highlight/detail?id=1140742156","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140742156?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:14","pubTimestamp":1778634881,"startTime":"0","endTime":"0","summary":"Immunovant, Inc.计划于2026年05月20日（盘前）发布财报，市场关注亏损路径与管线重估进展。市场一致预期本季度Immunovant, Inc.营收为0.00美元，同比持平；每股收益预计为-0.60美元，同比改善16.15%；息税前利润预计为-1.21亿美元，同比变化0.03%。上一季度Immunovant, Inc.营收为0.00美元，同比持平；毛利率不适用；归属于母公司股东的净亏损为1.11亿美元，净利率不适用；每股亏损为-0.61美元，同比改善19.74%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Immunovant, Inc.本季度营收预计持平，管线试验挫折成变数","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115169106","title":"异动解读 | Immunovant发布第三季度财务业绩，盘中大涨11.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115169106","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115169106?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:56","pubTimestamp":1770389766,"startTime":"0","endTime":"0","summary":"Immunovant, Inc.(IMVT)今日盘中大涨11.72%，引起了市场的广泛关注。消息面上，Immunovant, Inc.于今日盘前正式发布了截至2025年12月31日的第三季度财务报告，同时披露了公司在业务运营方面的关键进展。这份财务业绩的公布，为投资者提供了评估公司近期表现和未来前景的重要依据，可能是推动股价上涨的主要因素。该公司此次公布的第三季度财务报告涵盖了详尽的财务数据和业务更新，这些信息通常会对市场情绪产生显著影响，并直接反映在股价变动上。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177445822","title":"Immunovant公布企业最新进展及2025年12月31日截止第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1177445822","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177445822?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:01","pubTimestamp":1770379308,"startTime":"0","endTime":"0","summary":"Immunovant, Inc.近日披露了公司最新动态，并正式发布了截至2025年12月31日的第三季度财务报告。此次公告涵盖了公司在业务运营方面的关键更新以及详尽的财务数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518277747","title":"Guggenheim：重申Immunovant(IMVT.US)评级，由买入调整至买入评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277747","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518277747?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:25","pubTimestamp":1741623919,"startTime":"0","endTime":"0","summary":"Guggenheim：重申Immunovant(IMVT.US)评级，由买入调整至买入评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11002548640656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517923782","title":"Immunovant, Inc.盘中异动 下午盘急速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517923782","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517923782?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:09","pubTimestamp":1741201780,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时09分，Immunovant, Inc.股票出现异动，股价急速上涨5.03%。截至发稿，该股报19.42美元/股，成交量41.073万股，换手率0.24%，振幅4.16%。Immunovant, Inc.股票所在的生物技术行业中，整体涨幅为2.04%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为957.19%、307.92%、304.87%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Marker Therapeutics, Inc.，振幅分别为82.59%、54.27%、50.73%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306030940a26114f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306030940a26114f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMVTU","BK4585","BK4139","BK4588","IMVTW","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634234","title":"Immunovant, Inc.盘中异动 股价大跌5.07%报19.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634234","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634234?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:37","pubTimestamp":1741012660,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时37分，Immunovant, Inc.股票出现异动，股价快速跳水5.07%。截至发稿，该股报19.56美元/股，成交量5.6534万股，换手率0.03%，振幅4.61%。Immunovant, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Entero Therapeutics Inc.、Geovax Labs, Inc.、Alto Neuroscience, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为48.52%、33.60%、31.61%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Vincerx Pharma, Inc.，振幅分别为21.22%、19.25%、18.04%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223740abe6353f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223740abe6353f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMVTU","BK4139","IMVT","IMVTW","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513299488","title":"Immunovant, Inc.盘中异动 股价大涨5.04%报21.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299488","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513299488?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:47","pubTimestamp":1740149263,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时47分，Immunovant, Inc.股票出现波动，股价快速上涨5.04%。截至发稿，该股报21.48美元/股，成交量6.2287万股，换手率0.04%，振幅3.33%。Immunovant, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Omega Therapeutics, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为82.80%、82.33%、30.61%，振幅较大的相关个股有Osr Holdings Inc C/Wts 09/02/2028 、Omega Therapeutics, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为46.92%、35.45%、33.83%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221224743a24eb474&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221224743a24eb474&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMVT","BK4585","IMVTW","IMVTU","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165963","title":"Immunovant, Inc.盘中异动 快速拉升5.02%报21.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165963","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165963?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:43","pubTimestamp":1739889809,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时43分，Immunovant, Inc.股票出现波动，股价大幅上涨5.02%。截至发稿，该股报21.35美元/股，成交量3.9537万股，换手率0.02%，振幅4.06%。Immunovant, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为303.62%、108.85%、87.42%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.、Pulmatrix, Inc.，振幅分别为34.04%、26.83%、23.16%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224329abd3b1ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224329abd3b1ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMVTW","BK4585","IMVTU","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510896480","title":"Immunovant, Inc.盘中异动 股价大跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510896480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510896480?lang=zh_cn&edition=full","pubTime":"2025-02-11 02:29","pubTimestamp":1739212142,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日02时29分，Immunovant, Inc.股票出现异动，股价大幅下挫5.24%。截至发稿，该股报19.34美元/股，成交量134.362万股，换手率0.79%，振幅8.43%。Immunovant, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Biodexa Pharmaceuticals Plc、Dominari Holdings Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为3063.98%、1638.48%、1333.54%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Abpro Holdings Inc C/Wts 12/11/2029 、Biodexa Pharmaceuticals Plc，振幅分别为99.86%、87.80%、87.71%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211022903a240d2f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211022903a240d2f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","IMVTW","BK4139","IMVT","IMVTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510850397","title":"Guggenheim：维持Immunovant(IMVT.US)评级，由买入调整至买入评级, 目标价由46.00美元调整至44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510850397","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510850397?lang=zh_cn&edition=full","pubTime":"2025-02-10 21:52","pubTimestamp":1739195541,"startTime":"0","endTime":"0","summary":"Guggenheim：维持Immunovant(IMVT.US)评级，由买入调整至买入评级, 目标价由46.00美元调整至44.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/10215248063272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159397865","title":"Immunovant 2025年第三季度GAAP每股收益$(0.76)，符合预期，截止2024年12月31日的备考现金余额约为8.25亿美元，包括约4.5亿美元的私人配售总收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1159397865","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159397865?lang=zh_cn&edition=full","pubTime":"2025-02-06 19:42","pubTimestamp":1738842172,"startTime":"0","endTime":"0","summary":"Immunovant 报告季度每股亏损$，符合分析师预期。这比去年同期每股亏损$增加了111.11%。以上内容来自Benzinga Earnings专栏，原文如下：Immunovant  reported quarterly losses of $ per share which met the analyst consensus estimate. This is a 111.11 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immunovant 2025年第三季度GAAP每股收益$(0.76)，符合预期，截止2024年12月31日的备考现金余额约为8.25亿美元，包括约4.5亿美元的私人配售总收益","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508828142","title":"Immunovant, Inc.盘中异动 大幅下跌5.15%报20.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508828142","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508828142?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:07","pubTimestamp":1738595249,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时07分，Immunovant, Inc.股票出现波动，股价急速跳水5.15%。截至发稿，该股报20.62美元/股，成交量14.1163万股，换手率0.08%，振幅3.31%。Immunovant, Inc.股票所在的生物技术行业中，整体跌幅为0.72%。其相关个股中，Hcw Biologics Inc.、Invivyd, Inc.、Gh Research Plc涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为500.44%、395.41%、260.41%，振幅较大的相关个股有Hcw Biologics Inc.、Invivyd, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为136.56%、71.79%、50.76%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230729a238117a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230729a238117a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMVTU","BK4585","BK4139","IMVT","IMVTW","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500112349","title":"Wolfe Research：下调Immunovant(IMVT.US)评级，由优于大市调整至Peer Perform评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500112349","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500112349?lang=zh_cn&edition=full","pubTime":"2025-01-03 22:52","pubTimestamp":1735915948,"startTime":"0","endTime":"0","summary":"Wolfe Research：下调Immunovant(IMVT.US)评级，由优于大市调整至Peer Perform评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/03225247115140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492380177","title":"富国银行：维持Immunovant评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492380177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492380177?lang=zh_cn&edition=full","pubTime":"2024-12-19 23:08","pubTimestamp":1734620887,"startTime":"0","endTime":"0","summary":"富国银行：维持immunovant(IMVT.US)评级，由增持调整至增持评级,目标价由47.00美元调整至45.00美元。Immunovant(IMVT.US)公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。它致力于让自身免疫性疾病患者能够正常生活。该公司的产品包括batoclimab和针对新生儿Fc受体(FcRn)的IMVT-1402。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219231501a1fb6b12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219231501a1fb6b12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492338201","title":"Immunovant, Inc.盘中异动 早盘急速下挫5.41%报26.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492338201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492338201?lang=zh_cn&edition=full","pubTime":"2024-12-18 23:50","pubTimestamp":1734537028,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日23时50分，Immunovant, Inc.股票出现波动，股价快速下挫5.41%。截至发稿，该股报26.40美元/股，成交量12.4937万股，换手率0.09%，振幅5.23%。Immunovant, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Polyrizon Ltd.、Cognition Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com涨幅较大，Polyrizon Ltd.、Cognition Therapeutics, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为2484.32%、490.72%、291.62%，振幅较大的相关个股有Polyrizon Ltd.、Cognition Therapeutics, Inc.、Nkgen Biotech Inc C/Wts 31/05/2028，振幅分别为227.62%、118.27%、66.83%。Immunovant, Inc.公司简介：Immunovant Inc.是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121823502895ea5668&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121823502895ea5668&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMVTU","IMVTW","IMVT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":0.0465},{"period":"3month","weight":0.3775},{"period":"6month","weight":0.5136},{"period":"1year","weight":1.1408},{"period":"ytd","weight":0.5488}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immunovant, Inc.于2018年12月6日在特拉华州注册成立，是一家临床阶段的免疫学企业，专注于开发自身免疫性疾病的治疗方法。主要推进FCRN抑制剂IMVT-1402靶向由致病性IgG抗体引发的自身免疫性疾病，此前还开发了另一种抗FCRN抗体batoclimab。该公司对其主要候选药物进行跨越内分泌学、神经病学、风湿病学和皮肤病学等多个疾病领域的临床研究，与HanAll合作设计高效抗-FCRN抗体，并已停止batoclimab的进一步开发以全面专注于IMVT-1402的临床进展，将batoclimab项目的试验运营经验和临床见解应用于其核心产品开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.03669},{"month":7,"riseRate":0.625,"avgChangeRate":0.038118},{"month":8,"riseRate":0.571429,"avgChangeRate":0.080342},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immunovant, Inc.(IMVT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immunovant, Inc.(IMVT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}